LivaNova stock hits 52-week high at $68.00 By Investing.com
LivaNova PLC (LIVN) stock reached a new 52-week high of $68.00, representing a significant increase of nearly 110% from its 52-week low. Despite not being profitable in the past twelve months, analysts predict net income growth this year and profitability by 2026, driven by strategic initiatives, product developments, and favorable regulatory decisions like increased Medicare reimbursement rates for its VNS Therapy. The company's financial health is rated "GREAT" by InvestingPro, and it operates with moderate debt, making it appear slightly undervalued.
Piper Sandler reiterates Livanova stock rating on FY26 upside view
Piper Sandler has reiterated an Overweight rating and an $85.00 price target for Livanova (NASDAQ:LIVN), citing an expected upside in fiscal year 2026. The firm anticipates the company will guide to 5-7% revenue growth and adjusted earnings per share of $4.10 to $4.25 for FY26, alongside potential benefits from recent reimbursement changes for its epilepsy franchise. This positive outlook is supported by a strong gross profit margin and solid cash generation, with Piper Sandler identifying Livanova as a favored small- to mid-cap value name.
LivaNova stock hits 52-week high at $68.00 By Investing.com
LivaNova PLC stock reached a 52-week high of $68.00, marking a significant increase of almost 110% from its 52-week low. Analysts anticipate future profitability for the medical technology company in 2026, with an upcoming earnings report on February 25 potentially serving as a further catalyst for price movement. Recent positive developments include new analyst ratings, a key commercialization appointment, and increased Medicare reimbursement rates for its VNS Therapy.
LivaNova stock hits 52-week high at $68.00
LivaNova PLC stock has reached a new 52-week high of $68.00, representing a nearly 110% increase from its 52-week low. The company has seen a 41.83% rise in its stock price over the past year, with a 25.7% gain in the last six months, driven by strong investor confidence and strategic developments. Analysts anticipate profitability in 2026, and the company is considered slightly undervalued with a "GREAT" financial health score, ahead of its earnings report on February 25.
LivaNova (LIVN) to Release Quarterly Earnings on Wednesday
LivaNova (LIVN) is scheduled to release its Q4 2025 earnings before market open on Wednesday, February 25, 2026. Analysts project earnings of $0.80 per share and revenue of approximately $354.3 million for the quarter. The company currently holds a "Moderate Buy" consensus rating from analysts, with a target price of $69.38.
Cardiovascular Devices Market Booming Rapidly from 2026 to 2033
The Cardiovascular Devices market is projected to grow significantly, from USD 66,420.8 million in 2025 to USD 1,12,366.1 million by 2032, at a CAGR of 7.8%. A new report from Coherent Market Insights details this growth, analyzing market dynamics, key players like Livanova PLC and Medtronic PLC, and regional trends, with forecasts extending to 2033. The study aims to provide stakeholders with insights into market opportunities and challenges across various segments.
LivaNova PLC (NASDAQ:LIVN) Sees Large Growth in Short Interest
LivaNova PLC (NASDAQ:LIVN) experienced a significant 32.7% increase in short interest in January, reaching 2,436,767 shares, which represents 4.5% of its shares short and a 4.0-day short-interest ratio. Institutional ownership is high at 97.64%, with several firms adjusting their positions. Analysts maintain a "Moderate Buy" rating with an average target price of $69.38, while the stock trades around $65.80.
(LIVN) and the Role of Price-Sensitive Allocations
This article provides an AI-generated analysis of Livanova Plc (NASDAQ: LIVN), highlighting a near-term neutral sentiment amidst mid and long-term strength. It details specific institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report also emphasizes an exceptional risk-reward setup targeting an 8.5% gain.
LSV Asset Management Raises Stake in LivaNova PLC $LIVN
LSV Asset Management increased its stake in LivaNova PLC by 25.4% in the third quarter, now owning 1.24% of the company's stock valued at $35.34 million. Other institutional investors like Invesco, Artisan Partners, AQR Capital Management, Scopia Capital, and M&G PLC also significantly increased their holdings, with institutional investors now owning 97.64% of the shares. LivaNova, with a market capitalization of $3.59 billion, currently holds a "Moderate Buy" consensus rating from analysts, who project a target price of approximately $69.38.
Allianz Asset Management GmbH Makes New $7.69 Million Investment in LivaNova PLC $LIVN
Allianz Asset Management GmbH has made a new investment of $7.69 million in LivaNova PLC, acquiring 146,752 shares. This significant purchase highlights strong institutional interest in LivaNova, with other major funds also increasing their stakes. Analysts generally hold a "Moderate Buy" rating for the company, setting an average target price of $69.38.
New York State Common Retirement Fund Acquires 93,267 Shares of LivaNova PLC $LIVN
The New York State Common Retirement Fund significantly increased its stake in LivaNova PLC by acquiring an additional 93,267 shares, bringing its total holding to 180,008 shares valued at approximately $9.43 million. This comes as LivaNova receives a "Moderate Buy" rating from analysts with an average target price of $69.38. The company's stock shows a market capitalization of $3.6 billion and institutional ownership of about 97.64%.
Bioelectric Medicine Market is expected to reach US$ 235.55 billion by 2033 | Major key players - Medtronic Plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC
The Bioelectric Medicine Market, valued at US$ 31.34 billion in 2024, is projected to reach US$ 235.55 billion by 2033, demonstrating a CAGR of 22.3%. This growth is driven by the increasing demand for targeted, minimally invasive treatments and advancements in technology for managing various chronic conditions. Key players in this market include Medtronic Plc, Abbott Laboratories, Boston Scientific Corporation, and LivaNova PLC.
Responsive Playbooks and the LIVN Inflection
This article from Stock Traders Daily provides an AI-driven analysis of Livanova Plc (NASDAQ: LIVN), indicating strong sentiment across all time horizons. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights an exceptional risk-reward short setup and provides multi-timeframe signal analysis with support and resistance levels.
A Look At LivaNova (LIVN) Valuation After KeyBanc Upgrade And Renewed Medtech Optimism
LivaNova (LIVN) has drawn renewed investor attention following a KeyBanc upgrade, fueled by a positive outlook on Medical Technology stocks. The company's stock has seen significant short-term gains, trading at an estimated 27% discount to one intrinsic value measure. While the "fair value" based on cash flow suggests undervaluation at $73, other metrics like the Price-to-Sales ratio indicate a more balanced risk-reward profile, prompting investors to consider both the growth potential and inherent risks.
LivaNova PLC (NASDAQ:LIVN) Given Average Recommendation of "Moderate Buy" by Brokerages
Nine brokerages have given LivaNova PLC (NASDAQ:LIVN) an average recommendation of "Moderate Buy," with an average 12-month price target of $69.38. Institutional investors hold 97.64% of the company's stock, with several major funds increasing their stakes. LivaNova shares recently traded near a 12-month high at $65.71, with a market capitalization of $3.59 billion.
What LivaNova (LIVN)'s KeyBanc Upgrade and Medtech Reassessment Means For Shareholders
KeyBanc Capital Markets upgraded LivaNova PLC (LIVN) to Overweight, citing strong underlying trends in Medical Technology and a lowered valuation premium. This upgrade, alongside Goldman Sachs maintaining a Neutral stance, signifies increased institutional focus on LivaNova's role in the medtech landscape. The article explores how this upgraded view could impact LivaNova's investment narrative, especially concerning its path to sustainable profitability and the upcoming earnings report.
What LivaNova (LIVN)'s KeyBanc Upgrade and Medtech Reassessment Means For Shareholders
KeyBanc Capital Markets upgraded LivaNova (LIVN) to Overweight, citing strong underlying trends in Medical Technology and a reduced valuation premium. This upgrade, alongside Goldman Sachs maintaining a Neutral stance, signifies increased institutional interest in LivaNova's position within the medtech landscape. The article explores the implications of this upgrade for LivaNova's investment narrative, particularly regarding its path to profitability, upcoming earnings, and potential undervaluation.
LivaNova (LIVN) Upgraded to Overweight by KeyBanc
KeyBanc Capital Markets analyst Brett Fishbin upgraded LivaNova (LIVN) to Overweight from Sector Weight, setting an $81 price target and implying a 27% upside. This upgrade is based on KeyBanc's positive 2026 outlook for the Medical Technology segment, noting sustainable trends and disappearing valuation premiums. Goldman Sachs also recently reaffirmed a Neutral rating for LIVN, increasing its price target to $66.
LivaNova (LIVN) Upgraded to Overweight by KeyBanc
KeyBanc Capital Markets has upgraded LivaNova (LIVN) from Sector Weight to Overweight, setting an $81 target price due to sustainable trends in the medical technology segment. This upgrade is part of KeyBanc's positive 2026 outlook for Medical Technology. Goldman Sachs had previously reaffirmed a Neutral rating but increased its price target for LivaNova.
LivaNova stock reaches 52-week high at $65.95 By Investing.com
LivaNova PLC's stock recently hit a 52-week high of $65.95, reflecting a 29.55% increase over the past year and a 47.03% surge in six months. The company's performance is driven by strong demand for its medical devices and a gross profit margin of 69.41%, with analysts expecting profitability this year. Recent developments include a leadership change, increased price targets from Stifel and KeyBanc, and a significant boost in Medicare reimbursement rates for its VNS Therapy starting in 2026.
What are KeyBanc’s Top MedTech Picks By Investing.com
KeyBanc Capital Markets has identified LivaNova PLC, ICU Medical Inc, and Steris PLC as its top three MedTech picks due to their strong market positioning and growth potential. LivaNova leads with its Cardiopulmonary and Neuromodulation segments, ICU Medical is recognized for its infusion therapy products and recent acquisition, and Steris stands out for its sterilization and infection prevention solutions. Each company has received an Overweight rating and specific price targets from KeyBanc.
LivaNova stock reaches 52-week high at $65.95 By Investing.com
LivaNova PLC's stock has hit a 52-week high of $65.95, reflecting a 29.55% increase over the past year and a 47.03% surge in the last six months. This growth is attributed to strong demand for its medical devices and high investor confidence, with analysts expecting profitability this year. Recent developments, including analyst upgrades and increased reimbursement rates for its VNS Therapy, further bolster the positive outlook for the company.
LivaNova stock reaches 52-week high at $65.95
LivaNova PLC's stock has reached a 52-week high of $65.95, marking a 29.55% increase over the past year and a 47.03% surge in six months, driven by strong demand for its medical devices. Despite not being profitable in the last twelve months, the company boasts a healthy gross profit margin of 69.41% and analysts anticipate profitability this year. Recent developments, including analyst upgrades and expanded reimbursement rates for its VNS Therapy, further contribute to investor confidence.
LivaNova (LIVN) Upgraded to Overweight by KeyBanc
KeyBanc Capital Markets analyst Brett Fishbin upgraded LivaNova PLC (LIVN) to Overweight from Sector Weight, setting an $81 target price, implying an almost 27% upside. This upgrade is based on KeyBanc's positive 2026 outlook for the Medical Technology segment, noting sustainable trends and disappearing valuation premiums. Goldman Sachs had previously reaffirmed a Neutral rating for LivaNova, increasing its price target to $66.
LivaNova (LIVN) Upgraded to Overweight by KeyBanc
KeyBanc Capital Markets upgraded LivaNova (LIVN) from Sector Weight to Overweight, setting a target price of $81, indicating a 27% upside. This upgrade is based on KeyBanc's positive 2026 outlook for the Medical Technology segment, noting sustainable trends and a disappearing valuation premium. Goldman Sachs previously reaffirmed a Neutral rating for LIVN with an increased price target of $66.
Understanding the Setup: (LIVN) and Scalable Risk
This article analyzes Livanova Plc (NASDAQ: LIVN), noting a strong near-term sentiment moving towards a long-term positive bias. It highlights an exceptional 35.7:1 risk-reward setup, targeting a 10.6% gain with only 0.3% risk, and provides AI-generated institutional trading strategies for various risk profiles.
Emerald Mutual Fund Advisers Trust Purchases 26,202 Shares of LivaNova PLC $LIVN
Emerald Mutual Fund Advisers Trust increased its stake in LivaNova PLC (NASDAQ:LIVN) by 8.1% in the third quarter, acquiring an additional 26,202 shares to reach a total of 349,664 shares valued at approximately $18.3 million. This comes as institutional investors collectively own about 97.64% of LivaNova's stock. Analysts generally maintain a "Moderate Buy" rating for LivaNova, with a consensus target price of $69.38.
Cardiac Pacemaker Market Covering Prime Factors
The cardiac pacemaker market is experiencing growth driven by an aging global population, increased prevalence of cardiac rhythm disorders, and technological advancements like miniaturization and leadless pacemakers. Factors influencing this market also include regulatory processes, healthcare infrastructure, economic conditions, and clinical practice guidelines. Key players in this market include Medtronic Plc, Abbott Inc., and Boston Scientific Corporation.
SG Americas Securities LLC Reduces Stake in LivaNova PLC $LIVN
SG Americas Securities LLC significantly reduced its stake in LivaNova PLC (NASDAQ:LIVN) by 93.5% in the third quarter of 2025, selling 188,953 shares. Despite this reduction, other institutional investors like Goldman Sachs, UBS AM, MIRAE, and Intech increased their positions, maintaining the overall institutional ownership of the stock at about 97.64%. LivaNova currently trades around $63, with analysts holding a "Moderate Buy" consensus rating and an average price target of $69.38.
Extracorporeal Membrane Oxygenation (ECMO) Machines Market Set to Reach USD 708 Million by 2031 | Top Companies are Medtronic plc, LivaNova PLC, XENIOS AG.
The Extracorporeal Membrane Oxygenation (ECMO) Machines Market, valued at USD 553 million in 2022, is projected to reach USD 708 million by 2030, growing at a CAGR of 5.1% from 2024 to 2031. This growth is driven by recent industry developments in the US and Japan, including Medtronic's expanded ECMO platform, Getinge's production capacity increase, LivaNova's portable configurations, and Terumo's upgraded systems. The report highlights key companies and segmental analysis across modality, application, and component types.
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
LivaNova PLC will host a conference call on Wednesday, February 25, 2026, at 1 p.m. London time (8 a.m. EST) to discuss its fourth-quarter and full-year 2025 financial results. The medical technology company will release the results prior to the call, which will be accessible via audiocast on their website and by telephone. LivaNova, headquartered in London, specializes in medical solutions for neurological and cardiac conditions.
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
LivaNova PLC will host a conference call on Wednesday, February 25, 2026, at 1 p.m. London time (8 a.m. EST) to discuss its fourth-quarter and full-year 2025 financial results. The company will release the results before the call, and an audiocast will be available on their website. Participants can also join by telephone using the provided access code.
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
LivaNova PLC (Nasdaq: LIVN) will host a conference call on February 25, 2026, at 1 p.m. London time (8 a.m. EST) to discuss its fourth-quarter and full-year 2025 financial results. The medical technology company plans to release these results before the call, and an audiocast will be available on its website. A replay of the call will also be accessible on the Investors section of LivaNova's website.
Medical Implants Market Is Booming So Rapidly Growth by 2033 |Biotronik, Inc., Livanova Plc, NuVasive
The medical implants market is projected to grow significantly, from an estimated USD 126.29 billion in 2025 to USD 205.46 billion in 2032, at a CAGR of 7.2%. This growth is driven by rapid innovation, increasing investment, and shifting regional dynamics. The report provides a comprehensive analysis of market segmentation, key players like Biotronik Inc., Livanova Plc, and NuVasive Inc., and strategic insights for navigating upcoming opportunities.
Are Options Traders Betting on a Big Move in LivaNova Stock?
This article examines the options trading activity in LivaNova (LIVN) to determine if traders anticipate a significant price movement. It highlights key options details such as volume, open interest, and strike prices, noting a notable put/call ratio. The analysis suggests that while options activity can indicate potential volatility, it doesn't definitively predict stock direction.
LivaNova (NASDAQ:LIVN) Stock Price Crosses Above 50 Day Moving Average - Time to Sell?
LivaNova (NASDAQ:LIVN) recently crossed above its 50-day moving average, trading at $62.11 despite a slight dip of 1.7%. Analysts have a "Moderate Buy" consensus rating with a target price of $69.38, driven by several recent upgrades. The company shows a market capitalization of $3.39 billion, negative P/E, modest leverage, and high institutional ownership.
LivaNova chief legal officer Michael Hutchinson resigns; search for successor begins By Investing.com
Michael Hutchinson has resigned from his roles as Senior Vice President, Chief Legal Officer, and Company Secretary at LivaNova PLC, with his final day scheduled for January 26. He is leaving to pursue another opportunity. LivaNova, headquartered in London and listed on the NASDAQ Global Market, plans to hire an external search firm to find his successor.
LivaNova chief legal officer Michael Hutchinson resigns; search for successor begins
Michael Hutchinson has resigned from his roles as Senior Vice President, Chief Legal Officer, and Company Secretary at LivaNova PLC, effective January 26. He is leaving to pursue another opportunity, and LivaNova plans to hire an external search firm to find his successor. The company is headquartered in London and listed on the NASDAQ Global Market.
LivaNova chief legal officer Michael Hutchinson resigns; search for successor begins
Michael Hutchinson has resigned as Senior Vice President, Chief Legal Officer, and Company Secretary of LivaNova PLC, effective January 26, to pursue another opportunity. The company, headquartered in London and listed on NASDAQ, will hire an external firm to find his replacement. This announcement was made via an SEC filing.
LivaNova PLC (LIVN) Stock Analysis: Exploring a 17% Potential Upside in the Medical Device Sector
LivaNova PLC (LIVN) is a medical technology company with a promising 17% potential upside, specializing in neurological and cardiac devices. Despite negative EPS and ROE, indicating a reinvestment phase, the company shows strong revenue growth and free cash flow. Analyst sentiment is positive, with a target price of $73.00, and technical indicators suggest stable momentum, making it an attractive long-term investment in the medical technology sector.
The Technical Signals Behind (LIVN) That Institutions Follow
This article analyzes the technical signals for Livanova Plc (LIVN), indicating a neutral near and mid-term outlook with a possible moderation of a long-term positive bias. It highlights a significant 39.1:1 risk-reward setup targeting an 11.1% gain against 0.3% risk. The analysis also presents AI-generated institutional trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging.
LivaNova (LIVN) Is Up 6.2% After Fresh Analyst Optimism on Advanced Therapies Portfolio - What's Changed
LivaNova (LIVN) has seen a 6.2% increase following renewed analyst optimism regarding its advanced therapies portfolio. This positive sentiment stems from improved US reimbursement for VNS Therapy procedures and raised revenue guidance, despite ongoing risks related to high R&D spend and regulatory demands. LivaNova anticipates $1.6 billion in revenue and $168.9 million in earnings by 2028, with a fair value estimated at $69.10, representing a 7% upside.
LivaNova PLC (NASDAQ:LIVN) Given Average Rating of "Moderate Buy" by Analysts
LivaNova PLC (NASDAQ:LIVN) has received an average rating of "Moderate Buy" from nine research firms, with analysts setting a mean 12-month target price of $65.63. The company's stock is currently trading near its 52-week high, with a market cap of approximately $3.5 billion. Institutional ownership is high at almost 97.64%, with several major hedge funds increasing their stakes.
Stifel raises Livanova stock price target to $70 on cardiopulmonary growth
Stifel has increased its price target for Livanova (NASDAQ: LIVN) to $70.00 from $65.00, maintaining a Buy rating. This upgrade is driven by the consistent double-digit growth in Livanova's Cardiopulmonary business, which constitutes 57% of its sales. The firm anticipates strong EPS growth and sees potential upside from the resolution of a years-long litigation and opportunities in the obstructive sleep apnea market.
Stifel raises Livanova stock price target to $70 on cardiopulmonary growth
Stifel has raised its price target for Livanova (NASDAQ:LIVN) to $70.00 from $65.00, maintaining a Buy rating, driven by strong performance in the company's cardiopulmonary business. This segment, accounting for 57% of sales, has shown three consecutive years of double-digit revenue growth. The firm also anticipates potential operating expense reductions and the conclusion of a long-standing litigation, which could steer investor focus back to Livanova's core business and opportunities in the obstructive sleep apnea market.
6 Analysts Assess LivaNova: What You Need To Know
Six analysts have recently evaluated LivaNova (NASDAQ: LIVN), providing an average price target of $71.0, an increase of 9.57% from the previous average. The company, focused on cardiopulmonary and neuromodulation solutions, reported a revenue growth of 12.46% as of September 30, 2025, and demonstrates strong financial health with a net margin of 7.49% and a low debt-to-equity ratio of 0.42. Analysts' ratings and price target adjustments reflect evolving market conditions and company performance.
LIVN: Stifel Raises Price Target to $70, Maintains Buy Rating
Stifel has maintained a Buy rating on LivaNova (LIVN) and increased its price target to $70, signaling continued analyst confidence. This follows several other positive adjustments from firms like Keybanc, Mizuho, and Baird in recent months, with an average target price of $69.85 among 11 analysts. LivaNova, a UK-based medical device firm, specializes in cardiopulmonary solutions and neuromodulation devices for epilepsy and depression.
Precision Trading with Livanova Plc (LIVN) Risk Zones
This article provides a detailed analysis of Livanova Plc (LIVN) using AI-generated signals, identifying weak near-term sentiment but long-term strength. It outlines specific institutional trading strategies including position, momentum breakout, and risk hedging, complete with entry zones, targets, and stop losses. The analysis highlights a 36.3:1 risk-reward short setup and offers multi-timeframe signal insights for traders.
LivaNova stock tests investor patience as Wall Street weighs turnaround against volatility
LivaNova's stock concluded a volatile year with cautious consolidation, as investors debate its potential for a slow-burn recovery against continued underperformance risks. Despite a double-digit percentage gain for year-long holders, recent trading patterns show a lack of significant catalysts and a balanced, slightly positive Wall Street sentiment. The company's future hinges on healthcare system normalization, margin protection, and regulatory milestones in neuromodulation and cardiovascular solutions.
LivaNova CEO talks growth roadmap as company targets sleep apnea, depression therapies
LivaNova CEO Vladimir Makatsaria discusses the company's strategic roadmap, highlighting growth in its existing cardiopulmonary and epilepsy businesses while pursuing significant opportunities in obstructive sleep apnea (OSA) and difficult-to-treat depression. The company aims to expand its neuromodulation capabilities and introduce differentiated therapies, including its investigational aura6000 system for OSA and a potential new therapy for depression awaiting CMS coverage. Makatsaria emphasizes the company's strong foundation, market leadership, and focus on addressing unmet patient needs.
